GHRP-6

GHRP-6 is a synthetic hexapeptide and one of the first growth hormone-releasing peptides ever developed, a foundational member of the secretagogue class characterized by Bowers and colleagues ^[1]. It is a ghrelin-receptor agonist that releases growth hormone through a dual action on the hypothalamus and pituitary, distinct from growth hormone-releasing hormone ^[1][3].

As a research tool GHRP-6 helped define the biology that later led to the discovery of ghrelin and the growth hormone secretagogue receptor. It stimulates the body's own growth hormone rather than supplying the hormone directly, and it is a notably strong driver of appetite ^[1].

Its research applications fall into two streams. The endocrine literature uses GHRP-6 to probe growth hormone regulation; central injection studies show it acts largely at the hypothalamus, where its growth hormone release can be blocked by somatostatin, and it has been evaluated as a stimulation test for growth hormone reserve and pituitary stalk integrity ^[2][3]. A second, striking stream is cardiovascular; acting in part through the scavenger receptor CD36 and independently of the growth hormone pathway, GHRP-6 has shown cardioprotective effects, reducing oxidative damage and necrosis in models of myocardial infarction ^[5] and preventing doxorubicin-induced cardiac and multi-organ injury by activating pro-survival mechanisms ^[4].

GHRP-6 is not an approved general medicine and is used as a research peptide; its appetite-stimulating and growth hormone-releasing actions are well characterized in animals and humans. It is supplied as a lyophilized peptide for reconstitution.

GHRP-6 is a growth-hormone secretagogue that markedly stimulates appetite and, by raising GH and IGF-1, can cause water retention and edema, joint pain, numbness or tingling, and reduced insulin sensitivity with higher blood glucose. It can also modestly increase cortisol and prolactin. Human long-term safety data are limited and it is unapproved; sustained GH/IGF-1 elevation carries theoretical tissue-overgrowth concerns, so it should be considered experimental.

GHRP-6 is the first fully characterized growth hormone-releasing hexapeptide, developed by Cyril Y. Bowers and colleagues, and it holds a foundational place in endocrine history. It emerged from the observation that certain enkephalin-derived peptides could release growth hormone through a mechanism separate from growth hormone-releasing hormone, a discovery Bowers traced to the mid-1970s.

GHRP-6 became the prototype used to demonstrate that these peptides act at both the hypothalamus and the pituitary, and studies with it were instrumental in the search that led to identification of the growth hormone secretagogue receptor in 1996 and the endogenous hormone ghrelin in 1999. Its reliable growth hormone response also saw it employed diagnostically in tests of growth hormone secretion. Beyond endocrinology, later animal research uncovered a distinct, growth-hormone-independent cytoprotective action.

GHRP-6 is regarded with a certain reverence as one of the original growth hormone-releasing hexapeptides, the molecule that helped open the entire field of growth hormone secretagogues and, eventually, ghrelin biology. Researchers find its profile unusually broad for a single peptide, pairing a robust pulse of natural growth hormone and a marked appetite boost with a separate, much-studied cytoprotective action through the CD36 receptor that has reduced oxidative damage and tissue necrosis in animal models of heart injury. That two-sided biology gives it lasting scientific interest. In fairness, it remains a research peptide rather than an approved drug, and its strong stimulation of hunger may be unwanted for some purposes. Its historical importance and its intriguing cardioprotective findings nonetheless keep it a compound of enduring appeal.